Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-HOBA in Early Alzheimer's Patients
NCT06432166Phase 2Not yet recruiting
- Sponsor
- MTI Biotech
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 2-hydroxybenzylamine in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by MTI Biotech. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
2-hydroxybenzylamine
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06432166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432166.